Nath Jyotiman, Sarma Gautam, Paul Moumita, Bhattacharyya Mouchumee, Kalita Apurba Kumar, Medhi Partha Pratim
Department of Radiation Oncology, Dr B Borooah Cancer Institute, Guwahati, India.
Department of Radiation Oncology, All India Institute of Medical Sciences, Guwahati, Assam India.
Indian J Surg Oncol. 2023 Sep;14(3):699-706. doi: 10.1007/s13193-023-01744-6. Epub 2023 Apr 21.
Head and neck cancer incidence is relatively higher in north-eastern states than in other parts of India. Intensity-modulated radiotherapy (IMRT) was first introduced in our institute in 2012 to cater the entire north-east. This study attempts to assess the treatment outcomes and prognostic factors of head and neck cancer patients who had been treated with definitive radiotherapy in our institute from 2012 to 2016 using IMRT. This is a single institutional retrospective study. Thirty-six patients of head and neck cancer other than nasopharynx primary treated with definitive radiotherapy using IMRT between 2012 to 2016 were evaluated. The survival was analyzed using the Kaplan-Meir method, and various clinicopathologic factors were compared. The median age of the study patients was 58 years (range 24-79 years). The majority of the patients (69.4%) were below the age of 50 years. Thirty-two patients (88.9%) were male, and only four (11.1%) were females. After a median follow-up time of 40 months (7-84 months), the 5-year overall survival (OS) was 42.1%. The stage at presentation and radiotherapy treatment time were found to be significant prognostic factors of the outcome. The treatment-related toxicities were within acceptable limits. This retrospective study has reported the outcome and treatment-related toxicities of initially treated HNC patients with IMRT from northeast India.
印度东北部各邦的头颈癌发病率相对高于印度其他地区。2012年，我院首次引入调强放射治疗（IMRT），以满足整个东北地区的需求。本研究旨在评估2012年至2016年期间在我院接受IMRT根治性放疗的头颈癌患者的治疗效果和预后因素。这是一项单机构回顾性研究。对2012年至2016年间接受IMRT根治性放疗的36例非鼻咽癌原发的头颈癌患者进行了评估。采用Kaplan-Meir法分析生存率，并比较各种临床病理因素。研究患者的中位年龄为58岁（范围24 - 79岁）。大多数患者（69.4%）年龄在50岁以下。32例患者（88.9%）为男性，仅4例（11.1%）为女性。中位随访时间为40个月（7 - 84个月）后，5年总生存率（OS）为42.1%。发现就诊时的分期和放疗治疗时间是预后的重要因素。治疗相关毒性在可接受范围内。这项回顾性研究报告了印度东北部最初接受IMRT治疗的头颈癌患者的治疗效果和治疗相关毒性。
